Screener
Syndax Pharmaceuticals SNDX Business Segments — Other Research And Development Expense
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Syndax Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:OtherResearchAndDevelopmentExpense.
The source filing: Syndax Pharmaceuticals’s 10-Q, filed April 30, 2026.
- Filed
- Apr 30, 2026, 4:04 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-197154
| March 31, 2026 | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Research and development expenses | ||
| Revumenib-related costs | 25,725 | 20,805 |
| Axatilimab-related costs | 9,633 | 19,711 |
| Other R&D programs | 162 | 921 |
| Personnel cost and other expenses | 19,298 | 16,531 |
| General and administrative expenses | ||
| Commercial related expenses | 7,721 | 10,825 |
| Personnel cost and other expenses | 16,701 | 19,082 |
Item 1: Financial Statements
FAQ
- What is Syndax Pharmaceuticals's business segments — other research and development expense?
- Syndax Pharmaceuticals (SNDX) reported business segments — other research and development expense of $162K in Q1 2026.
- How has Syndax Pharmaceuticals's business segments — other research and development expense changed year-over-year?
- Syndax Pharmaceuticals's business segments — other research and development expense decreased by 82.4% year-over-year, from $921K to $162K.
- What is the long-term trend for Syndax Pharmaceuticals's business segments — other research and development expense?
- Over 3 years (2022 to 2025), Syndax Pharmaceuticals's business segments — other research and development expense has grown at a -13.1% compound annual growth rate (CAGR), from $6.33M to $4.15M.
- What does business segments — other research and development expense mean?
- This encompasses ancillary research and development costs not directly tied to primary clinical trials, such as early-stage discovery, laboratory supplies, or specialized research equipment. It provides insight into the company's commitment to maintaining a pipeline of future therapeutic candidates. High spending here indicates a focus on long-term innovation and pipeline diversification.
Ask your AI about Syndax Pharmaceuticals's business segments — other research and development expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude